Basmisanil (; developmental codes RG-1662 and RO5186582) is a highly
selective inverse agonist
In pharmacology, an inverse agonist is a drug that binds to the same receptor as an agonist but induces a pharmacological response opposite to that of the agonist.
A neutral antagonist has no activity in the absence of an agonist or inverse agon ...
/
negative allosteric modulator of
α5 subunit-containing
GABAA receptors which is under development by
Roche
F. Hoffmann-La Roche AG, commonly known as Roche, is a Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics. Its holding company, Roche Holding AG, has shares listed on the SIX S ...
for the treatment of
cognitive impairment associated with
Down syndrome
Down syndrome or Down's syndrome, also known as trisomy 21, is a genetic disorder caused by the presence of all or part of a third copy of chromosome 21. It is usually associated with physical growth delays, mild to moderate intellectual dis ...
.
As of June 2016, it is no longer studied.
It is studied with schizophrenia patients.
See also
*
List of investigational antipsychotics
*
GABAA receptor negative allosteric modulator
*
GABAA receptor § Ligands
References
External links
Basmisanil - AdisInsight
Fluoroarenes
GABAA receptor negative allosteric modulators
Nicotinamides
Nootropics
Isoxazoles
{{Nervous-system-drug-stub